Skip to main content

Table 1 Patients’ characteristics in relation to BPH treatment.

From: Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?

Variable

Baseline

Overall

AB

5ARI

CT

% Standardized difference *

28273

24626

2309

1338

5ARI vs AB

CT vs AB

No. (%)

No. (%)

No. (%)

No. (%)

Mean age (± SD)

70.28 (9.46)

69.55 (9.36)

75.61 (8.72)

74.49 (8.25)

66.99

58.3

Age

      

 40–55

1699 (6.01)

1641 (6.66)

42 (1.82)

16 (1.20)

−24.22

−28.42

 56–65

7001 (24.76)

6579 (26.72)

248 (10.74)

174 (13.00)

−41.83

−34.89

 66–75

11,120 (39.33)

9819 (39.87)

791 (34.26)

510 (38.12)

−11.65

−3.6

 76–85

7054 (24.95)

5555 (22.56)

961 (41.62)

538 (40.21)

41.71

38.75

 >85

1399 (4.95)

1032 (4.19)

267 (11.56)

100 (7.47)

27.63

14.04

 Previous hospitalization for BPH

1312 (4.64)

1048 (4.26)

167 (7.23)

97 (7.25)

12.82

12.88

 Previous BPH surgery

98 (0.35)

88 (0.36)

7 (0.30)

3 (0.22)

−0.94

−2.47

 Previous BPH severity factors

854 (3.02)

715 (2.90)

95 (4.11)

44 (3.29)

6.58

2.22

 Previous BPH related therapy

16,491 (58.33)

14,220 (57.74)

1377 (59.64)

894 (66.82)

3.84

18.8

  1. Legend: AB: Alpha-blocker monotherapy; CT: Combination Therapy 5ARI; 5-alpha reductase inhibitors monotherapy; * Standardized difference greater than 10 % represents meaningful imbalance in explored variable between treatment groups